European Psychiatry - Volume 41 - April 2017

356 / 916

S352 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S303–S364
e-Poster Walk: Others - part 2
EW0716
Audit of patients with intellectual
disabilities accessing a specialist
neuropsychiatry service for epilepsy
management
A. Adetoki
a Coventry and Warwickshire NHS Partnership Trust, Coventry, UK
b Birmingham and Solihull NHS Foundation Trust, Birmingham, UK
Introduction Epilepsy is a frequent co-morbidity in patients with
intellectual disabilities, some of whom require specialist services.
The National institute for health and care excellence (NICE) has
recommended that there should be equity of access to high qua-
lity of care regardless of the existence of a diagnosis of intellectual
disability.
Objectives To observe current practice with regards to NICE gui-
delines for epilepsy care in patients with intellectual disability.
Aims To identify the level of compliance with NICE guidelines
and provide evidence which may inform care planning processes.
Methods A retrospective review of the electronic and paper-
based records of a total sample of intellectually disabled patients
who accessed a specialist neuropsychiatry service for the mana-
gement of epilepsy during a six-month period was carried
out.
Results The records of 21 patients whose ages ranged from 20
to 58 years were audited. The waiting period ranged from 4
weeks to 46 weeks. There was evidence of Carer involvement
in the management of 100% of the patients and seizure impro-
vement since referral was documented in 66%. Non- medication
treatment was offered in 67% of cases. Evidence of special conside-
rations in view of patient’s intellectual disability was recorded in
24%, best interest considerations in 24% and capacity assessment
in 19%.
Conclusions There is a significant improvement in the symptoms
of 66% of patients in this audit. However there is room for impro-
vement and a more specific plan for patients with intellectual
disabilities should facilitate this.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EW0717
Prevalence of ADHD symptoms among
adults in the general population in
Finland
L. Alaheino ∗, S. Leppämäki
Helsinki university central hospital, psychiatry, Helsinki, Finland
∗ Corresponding author.
Introduction Earlier considered a disorder affecting only children,
today worldwide adult ADHD prevalence is estimated at 2.5%. The
core symptoms; inattention, hyperactivity and impulsivity, often
persevere impacting many fields of life.
Objectives To estimate the prevalence of ADHD symptoms in the
general Finnish adult population.
Methods We started with a population based and randomly
drawn sample of 3000 adults, aged 18–44 years. When contacted,
participants were provided three alternative ways to partici-
pate (online, letter, telephone interview). Using the adult ADHD
rating scale (ASRS) screener all participants (n = 748) were cate-
gorized into groups: possibly symptomatic (≥4 points), controls
(≤ 2 points) and undefined (3 points). Fifty-seven possibly symp-
tomatic consented to further evaluation by a telephone interview,
together with two age- and gender matched controls each.
Results Using the results from the ASRS screener, we calculated
a 10.96% prevalence. Analysis of the complete ASRS resulted in a
5.08% and the recommended two-step evaluation in a 3.34% pre-
valence, out of whom two thirds considered being moderately or
severely impaired by the symptoms.
Conclusions This study suggests that a large number of adults in
the general population are negatively affected by ADHD symptoms,
almost all unrecognized by health care professionals. As ADHD is
a burden for the patient, his family and the society, adult ADHD
deserves greater attention in the future.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0718
Health-related quality of life and work
productivity of adults with ADHD:
A UK web-based survey
P. Asherson ∗, C. Kosmas , C. Patel , H. Doll , A. Joseph
a Institute of psychiatry, psychology and neuroscience, London,
United Kingdom
b ICON clinical research UK Ltd, Abingdon, United Kingdom
c Shire, Zug, Switzerland
∗ Corresponding author.
Introduction European data on health-related quality of life
(HRQoL) in adults with attention deficit/hyperactivity disorder
(ADHD) in the general population is sparse.
Aims and objectives To report HRQoL in UK adults with ADHD.
Methods UK residents aged 18–55 years with a diagnosis of
adult ADHD completed an online, cross-sectional survey inclu-
ding questions on disease history, the EuroQol Five Dimensions
questionnaire with five-levels (EQ-5D-5L) and the Work pro-
ductivity and activity impairment questionnaire: general health
(WPAI:GH). ADHD symptom severity was assessed by tele-
phone using ADHD rating scale version IV with adult prompts
(ADHD-RS-IV).
Results The survey was completed by 233 participants (65.2%
women; 77.3% white British), mean age 32.6 years (standard devia-
tion [SD] 9.5), mean ADHD-RS-IV total score 43.46 (SD 7.88). Their
mean EQ-5D-5L utility score of 0.74 (SD 0.21) was lower than the
UK population norm of 0.86 (SD 0.23) PAI:GH scores indi-
cated that health problems resulted in impairments of 32.04% in
work productivity and 45.79% in regular daily activities. Regression
analyses adjusting for gender, age and co-morbidities demonstra-
ted associations between EQ-5D-5L utility scores and gender (men
had lower scores, P < 0.001), work impairment due to health pro-
blems (increasing impairment was associated with lower scores,
P = 0.005) and age (for each additional year of age, scores decreased
by 0.007, P = 0.010).
Conclusions These results highlight the impact on health utility,
work productivity and regular daily activities, and add to the des-
cription of the disease burden of adult ADHD in the UK.
This study was funded by Shire Development LLC.
Disclosure of interest Kings College London research support
account for Asherson received honoraria for consultancy to Shire,
Eli-Lilly and Novartis educational/research awards fromShire, Lilly,
Novartis, Vifor Pharma, GW Pharma and QbTech speaker at spon-
sored events for Shire, Lilly and Novartis.
Reference
[1] Kind. . 1999.